Kyowa Kirin Pharmaceutical Development
KYKOYNext catalyst
Mogamulizumab
Cutaneous T-Cell Lymphoma, Relapsed
Get an email about KYKOY's next catalysts
Track Kyowa Kirin Pharmaceutical Development (KYKOY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
Mogamulizumab Phase 2 Est. Readout
Estimated primary completion for Mogamulizumab trial (NCT05996185) in T Cell Lymphoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
OPC-262
Diabetes, Type 2
KHK7580
Parathyroid Carcinoma
Vorinostat
Cutaneous T-Cell Lymphoma
Istradefylline (KW-6002)
Parkinson's Disease
KW-6500
Parkinson's Disease
KHK4827
Psoriasis
Istradefylline
Parkinson's Disease
KHK7791
Hyperphosphatemia
KW-0761
Adult T-cell Leukemia-lymphoma
Burosumab
X-linked Hypophosphatemia (XLH)
EN3267
Pain
KW-3357
Disseminated Intravascular Coagulation (DIC)
KRN23
Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
KW-2246 (fentanyl citrate)
Pain, Cancer
Romiplostim
Aplastic Anemia
Oral Phosphate Supplement
X-Linked Hypophosphatemia
darbepoetin alfa
Anemia
KHK7580 middle dose
Secondary Hyperparathyroidism
Mogamulizumab
Cutaneous T-Cell Lymphoma, Relapsed
Methylprednisone
Kidney Transplantation
ARQ 197
Non-small-cell Lung Cancer
KHK4083
Atopic Dermatitis
KW-6356
Parkinson's Disease
Pegfilgrastim
Peripheral Blood Stem Cell Transplantation
DA-EPOCH Protocol
T Cell Lymphoma
KRN7000
Chronic Hepatitis C
Topical NO
Anogenital Warts
SHP674
Acute Lymphoblastic Leukemia
KHK4951
Diabetic Macular Edema (DME)
KHK7580 high dose
Secondary Hyperparathyroidism
CHOEP protocol
T Cell Lymphoma
Aflibercept Injection
Neovascular Age-Related Macular Degeneration (nAMD)
KW-6002 (istradefylline)
Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OPC-262 | Phase 3 | Diabetes, Type 2 | - | - |
KHK7580 | Phase 3 | Parathyroid Carcinoma | - | - |
Vorinostat | Phase 3 | Cutaneous T-Cell Lymphoma | - | - |
Istradefylline (KW-6002) | Phase 3 | Parkinson's Disease | - | - |
KW-6500 | Phase 3 | Parkinson's Disease | - | - |
KHK4827 | Phase 3 | Psoriasis | - | - |
Istradefylline | Phase 3 | Parkinson's Disease | - | - |
KHK7791 | Phase 3 | Hyperphosphatemia | - | - |
KW-0761 | Phase 3 | Adult T-cell Leukemia-lymphoma | - | - |
Burosumab | Phase 3 | X-linked Hypophosphatemia (XLH) | - | - |
EN3267 | Phase 3 | Pain | - | - |
KW-3357 | Phase 3 | Disseminated Intravascular Coagulation (DIC) | - | - |
KRN23 | Phase 3 | Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | - | - |
KW-2246 (fentanyl citrate) | Phase 3 | Pain, Cancer | - | - |
Romiplostim | Phase 3 | Aplastic Anemia | - | - |
Oral Phosphate Supplement | Phase 3 | X-Linked Hypophosphatemia | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
KHK7580 middle dose | Phase 2 | Secondary Hyperparathyroidism | - | - |
Mogamulizumab | Phase 2 | Cutaneous T-Cell Lymphoma, Relapsed | - | - |
Methylprednisone | Phase 2 | Kidney Transplantation | - | - |
ARQ 197 | Phase 2 | Non-small-cell Lung Cancer | - | - |
KHK4083 | Phase 2 | Atopic Dermatitis | - | - |
KW-6356 | Phase 2 | Parkinson's Disease | - | - |
Pegfilgrastim | Phase 2 | Peripheral Blood Stem Cell Transplantation | - | - |
DA-EPOCH Protocol | Phase 2 | T Cell Lymphoma | - | - |
KRN7000 | Phase 2 | Chronic Hepatitis C | - | - |
Topical NO | Phase 2 | Anogenital Warts | - | - |
SHP674 | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
KHK4951 | Phase 2 | Diabetic Macular Edema (DME) | - | - |
KHK7580 high dose | Phase 2 | Secondary Hyperparathyroidism | - | - |
CHOEP protocol | Phase 2 | T Cell Lymphoma | - | - |
Aflibercept Injection | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
KW-6002 (istradefylline) | Phase 2 | Parkinson's Disease | - | - |
Frequently asked questions
What is in Kyowa Kirin Pharmaceutical Development's drug pipeline?→
CatalystAlert tracks 33 drug candidates in Kyowa Kirin Pharmaceutical Development's (KYKOY) pipeline across Phase 3, Phase 2. Its lead program is Burosumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kyowa Kirin Pharmaceutical Development's next FDA catalyst?→
Kyowa Kirin Pharmaceutical Development's (KYKOY) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KYKOY biotech catalysts?→
Add KYKOY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kyowa Kirin Pharmaceutical Development's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.